This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Evosyal

Strathspey Crown Holdings LLC

Drug Names(s): DWP450, DWP-450, GWP450, GWP-450, Nabota, Botulinum Toxin Type A (Biosimilar), Biosimilar Botox

Description: EVOSYAL is the botulinum toxin (biosimilar) consisting of high-purity 900kDa neurotoxin (Botox - Cosmetic).

Deal Structure: Daewoong and Evolus
In October 2013, Daewoong Pharmaceutical announced that it entered into a contract with U.S.-based Evolus to export Nabota (tentatively named), the botulinum toxin formulation. This contract confers on Evolus the exclusive right to supply and distribute Nabota (tentatively named) in the United States and Europe. This contract is worth approximately KRW 300 billion based on the five-year export value including the technical fees, which is the single largest export contract and paves the way for Daewoong Pharmaceutical to make inroads into developed countries.

Strathspey and Evolus
In October 2013, Strathspey Crown Holdings announced that it has acquired Evolus, for an undisclosed amount. As part of the transaction, Strathspey Crown's wholly-owned subsidiary, ALPHAEON Corporation, has received the exclusive license to market, in both the U.S. and several international markets, an advanced Botulinum toxin Type A neurotoxin developed by...See full deal structure in Biomedtracker

Partners: Daewoong Pharmaceutical Company Ltd.


Evosyal News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug